Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis

Biomarker efficacy in multiple sclerosis diagnosis and treatment

The goal in studies concerning biomarkers in autoimmune diseases is finding a marker which fluctuates in correlation with the disease’s severity and settles within normal borders after effective treatment. This marker would later be used as an efficient tool in diagnosis and analysis of medicine clout. It seems the most cogent biomarkers are those measurable in serum or plasma. MS is a neurolog...

Serum and Saliva Myelin Basic Protein as Multiple Sclerosis Biomarker

Objective: Multiple sclerosis (MS) is presented with motor and sensory function loss. It is caused by demyelination and following axonal lesion. As myelin basic protein (MBP) is one of the key elements of the myelin cover, we examined the level of MBP in serum, stimulated, and unstimulated saliva as a suitable biomarker for detecting MS. Methods: A case-control study was performed in 29 health...

CSF neurofilament light: A universal risk biomarker in multiple sclerosis?

Multiple Sclerosis in Iran

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system (CNS). This highlydisabling disorder is characterized by a variable clinical course. MS is a heterogeneous disease with acomplex pathology and significant social and economic impact. MS is associated with dysfunction ofparts of the nervous system which results in a range of signs and symptoms, ...

CXCL13 is a plasma biomarker of germinal center activity.

Significantly higher levels of plasma CXCL13 [chemokine (C-X-C motif) ligand 13] were associated with the generation of broadly neutralizing antibodies (bnAbs) against HIV in a large longitudinal cohort of HIV-infected individuals. Germinal centers (GCs) perform the remarkable task of optimizing B-cell Ab responses. GCs are required for almost all B-cell receptor affinity maturation and will be...